Brevibloc Double Strength In Plastic Container is a drug owned by Baxter Healthcare Corp. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 12, 2021. Details of Brevibloc Double Strength In Plastic Container's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US6310094 (Pediatric) | Ready-to-use esmolol solution |
Jul, 2021
(4 years ago) |
Expired
|
|
US6528540 (Pediatric) | Esmolol formulation |
Jul, 2021
(4 years ago) |
Expired
|
| US6310094 | Ready-to-use esmolol solution |
Jan, 2021
(4 years ago) |
Expired
|
| US6528540 | Esmolol formulation |
Jan, 2021
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Brevibloc Double Strength In Plastic Container's patents.
Latest Legal Activities on Brevibloc Double Strength In Plastic Container's Patents
Given below is the list of recent legal activities going on the following patents of Brevibloc Double Strength In Plastic Container.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| File Marked Found | 07 Aug, 2018 | US6310094 |
| Termination or Final Written Decision | 27 Apr, 2016 | US6310094 |
| Termination or Final Written Decision | 27 Apr, 2016 | US6528540 |
| Petition Requesting Trial | 19 Nov, 2015 | US6310094 |
| Petition Requesting Trial | 19 Nov, 2015 | US6528540 |
| File Marked Lost | 23 Mar, 2005 | US6310094 |
| Mail Miscellaneous Communication to Applicant | 18 Dec, 2003 | US6528540 |
| Miscellaneous Communication to Applicant - No Action Count | 17 Dec, 2003 | US6528540 |
| Patent Issue Date Used in PTA Calculation
Critical | 04 Mar, 2003 | US6528540 |
| Recordation of Patent Grant Mailed
Critical | 04 Mar, 2003 | US6528540 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets
invalidated somehow, the
generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal
pitfalls. Given
below are details of the litigation history of Brevibloc Double Strength In Plastic Container and ongoing
litigations to
help you estimate the early arrival of Brevibloc Double Strength In Plastic Container generic.
Brevibloc Double Strength In Plastic Container's Litigations
Brevibloc Double Strength In Plastic Container been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 19, 2015, against patent number US6528540. The petitioner Mylan Pharmaceuticals Inc., challenged the validity of this patent, with Baxter International Inc. as the respondent. Click below to track the latest information on how companies are challenging Brevibloc Double Strength In Plastic Container's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6310094 | November, 2015 |
Institution Denied
(27 Apr, 2016) | Baxter International Inc. et al. | Mylan Pharmaceuticals Inc. et al. |
| US6310094 | November, 2015 |
Terminated-Denied
(27 Apr, 2016) | Baxter International Inc. | Mylan Pharmaceuticals Inc. |
| US6528540 | November, 2015 |
Institution Denied
(27 Apr, 2016) | Baxter International Inc. et al. | Mylan Pharmaceuticals Inc. et al. |
| US6528540 | November, 2015 |
Terminated-Denied
(27 Apr, 2016) | Baxter International Inc. | Mylan Pharmaceuticals Inc. |
US patents provide insights into the exclusivity only within the United States, but
Brevibloc Double Strength In Plastic Container is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Brevibloc Double Strength In Plastic Container's family patents as well as insights into
ongoing legal events
on those patents.
Brevibloc Double Strength In Plastic Container's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Brevibloc Double Strength In Plastic Container's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 12, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Brevibloc Double Strength In Plastic Container Generic API suppliers:
Esmolol Hydrochloride is the generic name for the brand Brevibloc Double Strength In Plastic Container. 10 different companies have already filed for the generic of Brevibloc Double Strength In Plastic Container, with Eugia Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Brevibloc Double Strength In Plastic Container's generic
How can I launch a generic of Brevibloc Double Strength In Plastic Container before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Brevibloc Double Strength In Plastic Container's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Brevibloc Double Strength In Plastic Container's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Brevibloc Double Strength In Plastic Container -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 10 mg/mL, 10 mL vial | |||||
| 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags | 31 Jan, 2014 | 1 | 08 Jun, 2016 | 12 Jan, 2021 | Extinguished |
Alternative Brands for Brevibloc Double Strength In Plastic Container
There are several other brand drugs using the same active ingredient (Esmolol Hydrochloride) as Brevibloc Double Strength In Plastic Container. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Baxter Hlthcare |
| ||
| Hq Spclt Pharma |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Esmolol Hydrochloride, Brevibloc Double Strength In Plastic Container's active ingredient. Check the complete list of approved generic manufacturers for Brevibloc Double Strength In Plastic Container
About Brevibloc Double Strength In Plastic Container
Brevibloc Double Strength In Plastic Container is a drug owned by Baxter Healthcare Corp. Brevibloc Double Strength In Plastic Container uses Esmolol Hydrochloride as an active ingredient. Brevibloc Double Strength In Plastic Container was launched by Baxter Hlthcare in 1988.
Approval Date:
Brevibloc Double Strength In Plastic Container was approved by FDA for market use on 15 August, 1988.
Active Ingredient:
Brevibloc Double Strength In Plastic Container uses Esmolol Hydrochloride as the active ingredient. Check out other Drugs and Companies using Esmolol Hydrochloride ingredient
Dosage:
Brevibloc Double Strength In Plastic Container is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2GM/100ML | INJECTABLE | Prescription | INJECTION |